4basebio PLC
4BB.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £152,558 | £156,246 | £196,992 | £83,773 |
| - Cash | £26,114 | £34,604 | £2,718 | £3,069 |
| + Debt | £15,438 | £15,216 | £15,494 | £10,457 |
| Enterprise Value | £141,882 | £136,858 | £209,768 | £91,161 |
| Revenue | £1,174 | £605 | £328 | £268 |
| % Growth | 94% | 84.5% | 22.4% | – |
| Gross Profit | £126 | -£26 | £236 | £179 |
| % Margin | 10.7% | -4.3% | 72% | 66.8% |
| EBITDA | -£7,231 | -£7,952 | -£5,468 | -£4,102 |
| % Margin | -615.9% | -1,314.4% | -1,667.1% | -1,530.6% |
| Net Income | -£7,804 | -£6,605 | -£5,728 | -£4,110 |
| % Margin | -664.7% | -1,091.7% | -1,746.3% | -1,533.6% |
| EPS Diluted | -0.5 | -0.51 | -0.45 | -0.33 |
| % Growth | 2% | -13.3% | -36.4% | – |
| Operating Cash Flow | -£7,641 | -£5,564 | -£5,141 | -£3,191 |
| Capital Expenditures | -£322 | -£509 | -£188 | -£465 |
| Free Cash Flow | -£7,963 | -£6,073 | -£5,329 | -£3,656 |